Stay updated with breaking news from Peter Schmid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pembrolizumab cuts the risk of triple-negative breast cancer (TNBC) returning by 37 per cent in women who have already beaten the disease, a trial by Queen Mary University of London showed.
09.02.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of results from the Phase 3 KEYNOTE-522 trial in the Feb. 10, 2022 edition of the New England Journal of Medicine. Results showed that neoadjuvant ...
Keytruda treatment found to cut risk of aggressive cancer returning after surgery by more than a third
Mother-of-four Lesley Stephen, of Edinburgh, benefited from tucatinib and said she agreed to take the drug as part of a trial 'because I had nothing to lose' after other treatments failed to work.
It was a clear, sunny, blue-sky day the day I learned I had breast cancer. The brutally unexpected so often seems to happen on such days.